KALA BIO (KALA)

Last close As at 27/02/2026

USD0.38

0.00 (0.00%)

Market capitalisation

KALA BIO is a clinical-stage biotechnology company advancing its proprietary mesenchymal stem cell secretome (MSC-S) platform towards rare eye diseases, with lead candidate KPI-012 targeting ocular surface diseases.

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Todd Bazemore

    CEO

  • Mary Reumuth

    CFO